MarkWalterFrohlichMD

PubMed

• 95 citations
  Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
  Debraj GuhaThakurta, Nadeem A. Sheikh, Li-Qun Fan, Harini Kandadi, T. Craig Meagher, Simon J. Hall, Philip W. Kantoff, Celestia S. Higano, Eric J. Small, Thomas A. Gar...> ;Clinical Cancer Research. 2015 Aug 15
• 213 citations
  Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
  Lawrence Fong, Peter R. Carroll, Vivian Weinberg, Stephen Chan, Jera Lewis, John M. Corman, Christopher L. Amling, Robert A. Stephenson, Jeff Simko, Nadeem A. Sheikh, ...> ;Journal of the National Cancer Institute. 2014 Nov 1
• 21 citations
  Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T
  Eric J. Small, Celestia S. Higano, Philip W. Kantoff, James Boyd Whitmore, Mark W. Frohlich, Daniel P. Petrylak> ;Prostate Cancer and Prostatic Diseases. 2014 Jun 24
• 13 citations
  Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.
  Tomasz M. Beer, Paul F. Schellhammer, John M. Corman, L. Michael Glode, Simon J. Hall, James Boyd Whitmore, Mark W. Frohlich, David F. Penson> ;Urology. 2013 Aug 1
• 233 citations
  Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treat...
  Paul F. Schellhammer, Gerald W. Chodak, James Boyd Whitmore, Robert B. Sims, Mark W. Frohlich, Philip W. Kantoff> ;Urology. 2013 Jun 1
• 199 citations
  Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
  Nadeem A. Sheikh, Daniel P. Petrylak, Philip W. Kantoff, Corazon P. dela Rosa, Frances P. Stewart, Ling-Yu Kuan, James Boyd Whitmore, James B. Trager, Christian Heinri...> ;Cancer Immunology, Immunotherapy. 2013 Jan 1
• 25 citations
  Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer
  Philip W. Kantoff, Celestia S. Higano, Eric J. Small, James Boyd Whitmore, Mark W. Frohlich, Paul F. Schellhammer> ;Journal of the National Cancer Institute. 2012 Jul 18
• 19 citations
  Sipuleucel-T for the Treatment of Advanced Prostate Cancer
  Mark W. Frohlich> ;Seminars in Oncology. 2012 Jun 1
• An analysis to quantify the overall survival (OS) benefit of sipuleucel-T accounting for the crossover in the control arm of the IMPACT study.
  Nabhan C, Gomella LG, DeVries T, Whitmore JB, Frohlich MW, George DJ> ;J. Clin. Oncol.. 2012-02-10
• 41 citations
  Integrated Safety Data From 4 Randomized, Double-Blind, Controlled Trials of Autologous Cellular Immunotherapy With Sipuleucel-T in Patients With Prostate Cancer
  Simon J. Hall, Laurence Klotz, Allan J. Pantuck, Daniel J. George, James Boyd Whitmore, Mark W. Frohlich, Robert B. Sims> ;The Journal of Urology. 2011 Sep 1
• Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase III studies.
  Gomella LG, Nabhan C, Whitmore JB, Frohlich MW, George DJ> ;J. Clin. Oncol.. 2011-05-20
• Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phas...
  Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP> ;J. Clin. Oncol.. 2011-05-20
• Quality-of-life assessment in a randomized, double-blind study of sipuleucel-T in men with androgen-dependent prostate cancer.
  Beer TM, Schellhammer PF, Corman JM, Glode LM, Hall S, Xu Y, Frohlich MW, Penson DF> ;J. Clin. Oncol.. 2011-05-20
• 103 citations
  Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
  Tomasz M. Beer, Guy T. Bernstein, John M. Corman, L. Michael Glode, Simon J. Hall, Wayne L. Poll, Paul F. Schellhammer, Lori A. Jones, Yi Xu, Jelle Kylstra, Mark W. Fr...> ;Clinical Cancer Research. 2011 Jul 1
• Characterization of antigen-specific T-cell activation and cytokine expression induced by sipuleucel-T.
  Sheikh NA, Wesley JD, Chadwick E, Perdue N, Dela Rosa CP, Frohlich MW, Stewart FP, Urdal DL> ;J. Clin. Oncol.. 2011-03-01
• Subsequent treatment with APC8015F and its effect on survival in the control arm of phase III sipuleucel-t studies.
  George DJ, Nabhan C, Gomella LG, Whitmore JB, Frohlich MW> ;J. Clin. Oncol.. 2011-03-01
• 3901 citations
  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
  Philip W. Kantoff, Celestia S. Higano, N. Shore, E. Roy Berger, Eric J. Small, David F. Penson, Charles H. Redfern, Anna C. Ferrari, Robert Dreicer, Robert B. Sims, Yi...> ;The New England Journal of Medicine. 2010 Jul 23
• 54 citations
  A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.
  Prema P. Peethambaram, Michelle E. Melisko, Kristine Rinn, Steven R. Alberts, Nicole M. Provost, Lori A. Jones, Robert B. Sims, Lisa R. C. Lin, Mark W. Frohlich, John ...> ;Clinical Cancer Research. 2009 Sep 15
• 594 citations
  Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-T in advanced prostate cancer
  Celestia S. Higano, Paul F. Schellhammer, Eric J. Small, Patrick A. Burch, John Nemunaitis, Lianng Yuh, Nicole M. Provost, Mark W. Frohlich> ;Cancer. 2009 Aug 15
• 37 citations
  Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.
  Jorge A. Garcia, Jonathan E. Rosenberg, Vivian Weinberg, Janet H. Scott, Mark W. Frohlich, John W. Park, Eric J. Small> ;BJU International. 2007 Mar 1
• A randomized phase II study of Xcellerated T Cells with or without prior fludarabine therapy in patients with multiple myeloma (MM).
  Vij R, Berenson JR, Borrello IM, Spitzer G, Bashey A, Martin T, Boccia RV, Simic A, Siegel D, Frohlich MW> ;J. Clin. Oncol.. 2005-06-01
• A phase I/II study of Xcellerated T Cells in patients with chronic lymphocytic leukemia.
  Kipps TJ, Wierda WG, Castro JE, Keating MJ, Boccia RV, Steis R, Meyer J, Berenson RJ, Frohlich MW> ;J. Clin. Oncol.. 2005-06-01
• A phase II study of Xcellerated T Cells in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (NHL).
  Gribben JG, Stephenson JJ, Bartlett NL, Milder MS, Boccia RV, Redfern C, Mizuno VM, Hillson J, Berenson RJ, Frohlich MW> ;J. Clin. Oncol.. 2005-06-01
• 38 citations
  In vitro engagement of Cd3 and CD28 corrects T cell defects in chronic lymphocytic leukemia
  Mark Bonyhadi, Mark W. Frohlich, Angela L. Rasmussen, Christophe Ferrand, Laura Sue Grosmaire, Eric Robinet, Jose F. Leis, Richard T. Maziarz, Pierre Tiberghien, Ronal...> ;Journal of Immunology. 2005 Feb 15
• A phase I/II trial of CD3/CD28 activated T cells (Xcellerated T Cells) in patients with hormone refractory prostate cancer.
  Glode ML, Pantuck A, Higano CS, Meyer J, Hami L, Craig S, Berenson RJ, Frohlich MW> ;J. Clin. Oncol.. 2004-07-15
• Join now to see all

Lectures

• 18th Annual International Society for Cellular Therapy (ISCT) Meeting 
  International Society for Cellular Therapy, Seattle, Washington - 6/5/2012